Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$188,500.00
Jun 1, 2026
For-profit organization
Finalizing the Development of a Novel Drug-Device Product for the Treatment and Control of Bleeding Caused by Traumatic Injury
1043943
MACH32 Inc. is developing a novel drug-device combination comprising an autoinjector for the intramuscular (IM) administration of a proprietary formulation of concentrated Tranexamic acid (TXA) drug for treatment of trauma-related bleeding.
$80,000.00
Aug 1, 2025
For-profit organization
Development of IMSAFE, an Intramuscular Autoinjector to Control Bleeding
1033871
This project aims to develop a smaller, intramuscular autoinjector capable of delivering a concentrated formulation of tranexamic acid (TXA), a widely used antifibrinolytic for treating hemorrhage. The Firm’s current prototype can deliver up to 5 mL; however, user feedback from military and emergency responders indicates a strong preference for a more compact device. By formulating TXA at higher concentrations, the Firm has reduced the required injection volume to 2–3 mL. This enables the design of a smaller, more field-appropriate autoinjector without compromising therapeutic efficacy.
$30,000.00
Jun 1, 2024
For-profit organization
Formulation of Drug Solution and Prototype Optimization for Intramuscular Injection
1018592
MACH32 is developing a drug-device combination medical product for early intervention and treatment of severe hemorrhage. This device administers a large-volume dose of the antifibrinolytic drug tranexamic acid (TXA). It simplifies the delivery of TXA, a clinically proven generic drug that reduces the risk of death due to bleeding by ~ 30%. TXA is underused because it is difficult to deliver and requires intravenous access; less than 5% of eligible patients receive TXA in a timely manner. This project focuses on the development of a highly concentrated TXA formulation optimized for simple intramuscular delivery in autoinjector format.
$5,049.75
Sep 9, 2022
For-profit organization
MACH32 Inc.-2022-2023-997448
997448
The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Research and Development (R&D) partnerships between the Recipient and foreign organizations in order to support R&D on the Recipient’s technology and advance its commercialization.
$50,000.00
Mar 1, 2022
For-profit organization
Market Assessment for IMSAFE
987871
MACH32 plans to complete a market assessment for the top 2 IMSAFE markets, military, first responder. This assessment will include information on pricing, volumes, use cases, reimbursement, and channels. Information from this assessment will assist in negotiations with potential industry partners including investors and R&D collaborations.
$40,000.00
Jul 1, 2021
For-profit organization
Improvements of Aerosol Containment Tent (ACT) Device
974189
The objective of the proposed project is to improve the first prototype of the Aerosol Containment (ACT) medical device by collecting user feedback, conducting additional product testing and clinical research to better meet user needs. New data will also support regulatory submissions for the ACT in other jurisdictions besides Canada.
$5,419.00
Dec 20, 2020
For-profit organization
Innovation Assistance Program – Round 2.5
968992
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
$12,176.00
Jun 25, 2020
For-profit organization
Innovation Assistance Program – Round 2
961751
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
$28,925.00
Apr 15, 2020
For-profit organization
COVID-19 RESPONSE: Development of MACT - Pandemic negative pressure tent
948661
COVID-19 can be spread in an airborne manner through aerosolized droplets during medical procedures. Due to this concern many lifesaving interventions are not being used during the COVID-19 pandemic. The proposed medical device creates a portable negative pressure space to allow the utilization of lifesaving aerosol generating medical procedures and helps protect frontline workers from contamination and exposure to the deadly virus.
$10,164.00
Apr 1, 2020
For-profit organization
Innovation Assistance Program
951495
The funding provided from the IAP program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.